Towarzystwo Funduszy Inwestycyjnych PZU SA’s Neurocrine Biosciences NBIX Stock Holding History

Towarzystwo Funduszy Inwestycyjnych PZU SA’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53.1K	Hold	315	–	–	0.02%	455
2026 Q1	$41.5K	Sell	315 -76	-19%	-$10.1K	0.01%	463
2025 Q4	$55.5K	Hold	391	–	–	0.01%	402
2025 Q3	$54.9K	Sell	391 -1,389	-78%	-$188K	0.01%	398
2025 Q2	$224K	Sell	1,780 -70	-4%	-$8.03K	0.06%	145
2025 Q1	$205K	Hold	1,850	–	–	0.07%	132
2024 Q4	$253K	Hold	1,850	–	–	0.08%	103
2024 Q3	$213K	Buy	1,850 +110	+6%	+$15.1K	0.08%	110
2024 Q2	$240K	Hold	1,740	–	–	0.09%	94
2024 Q1	$240K	Hold	1,740	–	–	0.1%	92
2023 Q4	$229K	Buy	+1,740	New	+$200K	0.11%	82
2021 Q3	$141K	Hold	1,473	–	–	0.17%	70
2021 Q2	$143K	Hold	1,473	–	–	0.17%	74
2021 Q1	$143K	Hold	1,473	–	–	0.21%	66
2020 Q4	$141K	Buy	+1,473	New	+$142K	0.15%	58

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Towarzystwo Funduszy Inwestycyjnych PZU SA's NBIX Position: Q2 2026 in Review

Towarzystwo Funduszy Inwestycyjnych PZU SA held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 315 shares worth $53.1K. The position accounts for 0.02% of the portfolio, ranked #455.

Towarzystwo Funduszy Inwestycyjnych PZU SA first reported a position in NBIX in Q4 2020 and has held it in 15 quarters since. The position peaked at $253K in Q4 2024. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Towarzystwo Funduszy Inwestycyjnych PZU SA held 315 shares of Neurocrine Biosciences worth $53.1K as of Q2 2026.
Towarzystwo Funduszy Inwestycyjnych PZU SA left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up 0.02% of Towarzystwo Funduszy Inwestycyjnych PZU SA's portfolio in Q2 2026, its #455 holding.
Towarzystwo Funduszy Inwestycyjnych PZU SA first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 15 quarters since.
Towarzystwo Funduszy Inwestycyjnych PZU SA's Neurocrine Biosciences position peaked at $253K in Q4 2024.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Towarzystwo Funduszy Inwestycyjnych PZU SA's 13F filing for Q2 2026, filed 7 Aug 2026.